San Mateo, Calif.–based company Vium, leveraging a living informatics approach to accelerate preclinical drug discovery and development raised a $24 M through Series B financing led by existing investors Lux Capital and Data Collective (DCVC), with participation from Tony Fadell’s Future Shape LLC, Founders Fund Dolby Family Ventures.
Peter Hebert (Lux Capital Co-organizer and Managing Partner) and Zachary Bogue (Data Collective (DCVC) Co-Founder and Co-Managing Partner) joined the organization's Board of Directors. Wendel Barr, is assigned as President and CEO
Vium makes a living informatics stage for preclinical in vivo drug research., Customers run the range of biotechnology, pharmaceutical and computational drug discovery organizations, novel threaupatic labs and academia. Vium Cloud, The Vium Digital VivariumTM, and online Research Suite allow researchers to improve advances in researched bioengineered models.
The arrangement is completely authorized by AAALAC International.